Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Ginkgo Bioworks
DNA
|
$1.05B |
| 2 |
Peloton Interactive
PTON
|
$691M |
| 3 |
DoorDash
DASH
|
$456M |
| 4 |
Certara
CERT
|
$393M |
| 5 |
Service Corp International
SCI
|
$374M |
Top Sells
| 1 |
Alibaba
BABA
|
$2.33B |
| 2 |
Tesla
TSLA
|
$1.55B |
| 3 |
Moderna
MRNA
|
$1.41B |
| 4 |
Amazon
AMZN
|
$884M |
| 5 |
NetEase
NTES
|
$692M |
Sector Composition
| 1 | Consumer Discretionary | 27.71% |
| 2 | Healthcare | 26.02% |
| 3 | Technology | 19.32% |
| 4 | Communication Services | 12.04% |
| 5 | Financials | 4.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NCNA
251
NuCana
NCNA
$5.48M
| $9.44M | ﹤0.01% |
732
| – | – |
|
252
Alector
ALEC
$305M
| $7.77M | ﹤0.01% |
340,352
+39,524
| +13% | +$902K |
|
253
Fortive
FTV
$16.2B
| $6.9M | ﹤0.01% |
97,814
-11,248
| -10% | -$794K |
|
254
British American Tobacco
BTI
$122B
| $6.85M | ﹤0.01% |
194,106
-23,111
| -11% | -$815K |
|
255
Relay Therapeutics
RLAY
$710M
| $6.72M | ﹤0.01% |
213,089
+20,568
| +11% | +$648K |
|
256
Lyell Immunopharma
LYEL
$233M
| $6.33M | ﹤0.01% |
21,374
+8,433
| +65% | +$2.5M |
|
257
TJX Companies
TJX
$155B
| $5.73M | ﹤0.01% |
86,893
-8,270
| -9% | -$546K |
|
258
Sixth Street Specialty
TSLX
$2.32B
| $5.07M | ﹤0.01% |
+228,078
| New | +$5.07M |
|
|
UXIN
259
Uxin Ltd
UXIN
$722M
| $4.9M | ﹤0.01% |
17,761
| – | – |
|
260
American Well
AMWL
$113M
| $4.58M | ﹤0.01% |
25,128
+2,270
| +10% | +$414K |
|
|
SOHU
261
Sohu.com
SOHU
$467M
| $4.17M | ﹤0.01% |
200,140
| – | – |
|
|
SAGE
262
DELISTED
Sage Therapeutics
SAGE
| $3.82M | ﹤0.01% |
86,298
+6,033
| +8% | +$267K |
|
|
KLDO
263
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $3.6M | ﹤0.01% |
659,227
+766
| +0.1% | +$4.18K |
|
264
Summit Therapeutics
SMMT
$19.3B
| $2.19M | ﹤0.01% |
436,512
| – | – |
|
|
BRW
265
Saba Capital Income & Opportunities Fund
BRW
$349M
| $1.97M | ﹤0.01% |
216,396
-203,244
| -48% | -$1.85M |
|
|
UBX
266
DELISTED
Unity Biotechnology
UBX
| $1.77M | ﹤0.01% |
58,911
-171,500
| -74% | -$5.14M |
|
267
Korea Electric Power
KEP
$17.2B
| $1.62M | ﹤0.01% |
163,646
| – | – |
|
268
Adicet Bio
ACET
$60M
| $1.42M | ﹤0.01% |
181,626
| – | – |
|
269
Fortis
FTS
$24.8B
| $1.35M | ﹤0.01% |
30,457
| – | – |
|
270
WEC Energy
WEC
$34.7B
| $1.34M | ﹤0.01% |
15,233
| – | – |
|
271
Newmont
NEM
$83.7B
| $1.1M | ﹤0.01% |
20,172
+5,241
| +35% | +$284K |
|
|
APRN
272
DELISTED
Blue Apron Holdings, Inc. Class A Common Stock
APRN
| $1.09M | ﹤0.01% |
12,376
| – | – |
|
273
Exelon
EXC
$43.9B
| $1.08M | ﹤0.01% |
31,220
| – | – |
|
274
Jackson Financial
JXN
$6.65B
| $986K | ﹤0.01% |
+37,907
| New | +$986K |
|
275
Beam Therapeutics
BEAM
$2.11B
| $931K | ﹤0.01% |
10,700
+10,213
| +2,097% | +$889K |
|